Can Abilify (aripiprazole) cause skin rash and gastrointestinal symptoms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Abilify Cause Skin Rash and GI Symptoms?

Yes, Abilify (aripiprazole) can cause both skin rash and gastrointestinal symptoms, though these adverse effects occur at relatively low frequencies according to FDA labeling data.

Gastrointestinal Symptoms

Gastrointestinal symptoms are among the most common adverse effects of aripiprazole. According to FDA labeling data, the following GI symptoms occur more frequently with Abilify than placebo 1:

  • Nausea: 15% (vs 11% placebo) in adults; 11% (vs 4% placebo) in pediatric bipolar patients
  • Constipation: 11% (vs 7% placebo) in adults; 5% (vs 2% placebo) as adjunctive therapy
  • Vomiting: 11% (vs 6% placebo) in adults; 14% (vs 7% placebo) in pediatric autistic disorder patients
  • Dyspepsia: 9% (vs 7% placebo)
  • Abdominal discomfort: 3% (vs 2% placebo)

The GI symptoms typically appear early in treatment and are generally mild to moderate in severity. In clinical trials, 70-80% of GI adverse effects occurred within the first 2 weeks, 75-80% were mild in severity, and 60-65% resolved within the first month 2. This temporal pattern is critical for patient counseling—most GI symptoms are transient and self-limiting.

Clinical Management of GI Symptoms

  • Start at the minimal effective dose (10 mg/day) and titrate slowly after at least 2 weeks 3
  • Provide supportive care during the first 3-7 days when symptoms are most likely
  • Reassure patients that nausea and GI upset typically resolve within the first month
  • Consider dose reduction if symptoms are prohibitive, though discontinuation is rarely necessary for GI symptoms alone

Skin Rash

Skin rash occurs less frequently but is a documented adverse effect of aripiprazole. According to FDA labeling, rash occurs in approximately 2% of patients treated with Abilify (vs 1% placebo) 1. While the overall incidence is low, case reports document various cutaneous reactions ranging from mild to severe 4, 5, 6.

Types of Skin Reactions Reported

The spectrum of aripiprazole-induced skin reactions includes:

  • Mild morbilliform rash (most common)
  • Acneiform eruptions 6
  • Lichenoid drug reactions (rare but potentially severe) 5
  • Severe cutaneous adverse reactions (extremely rare)

Most skin reactions are mild and self-limited, not requiring drug discontinuation 4. However, severe reactions requiring medical and surgical intervention have been documented, though these are exceptional cases 5.

Clinical Approach to Rash

If rash develops:

  1. Grade the severity based on body surface area involved, symptoms (pruritus, tenderness), and functional impact
  2. Rule out other causes: infection, other medications, systemic disease
  3. For mild rash (<10% BSA): Continue aripiprazole with topical emollients and mild-to-moderate potency topical corticosteroids 7
  4. For moderate rash (10-30% BSA): Consider dermatology consultation and potential dose reduction
  5. Discontinue immediately if any signs of bullous eruption, mucosal involvement, or systemic symptoms suggesting DRESS or Stevens-Johnson syndrome

Important Caveats

The timing of adverse effects matters for clinical decision-making. Nausea and insomnia typically occur within the first 10-20% of patients during the initial days of treatment but are manageable and usually resolve within 3-7 days 3. Skin reactions may develop after days to weeks on treatment.

Rechallenge after rash can be dangerous. While mild rashes may resolve with drug interruption, rechallenge carries risk of more severe reactions, including potential type-I allergic reactions 8. If rash was significant enough to warrant discontinuation, switching to an alternative agent is generally safer than rechallenge.

Patient education is critical. Inform patients that GI symptoms are common but typically transient, occurring in the first 1-2 weeks and resolving within a month. Advise them to report any rash immediately for assessment, as early identification allows for appropriate management before progression to severe reactions.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.